Bullish signal on weekly chart
R1 | 3478.73 | Pivot 3454.87 | S1 | 3414.73 |
R2 | 3518.87 | S2 | 3390.87 | |
R3 | 3582.87 | S3 | 3326.87 |
Intraday fact check
In the last 16 years, only 2.28 % trading sessions saw intraday declines higher than 5 % .Contingent Liabilities Coverage
Company has sufficient cash reserves to pay off its contingent liabilities. (Source: Standalone Financials)Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 26.05% towards employee cost in the year ending Mar 31, 2020. (Source: Standalone Financials)Candle Formations Yesterday
Black Spinning Top was formed for AstraZenecaFound Insights useful?
AstraZeneca Pharma surges 10% as WHO gives nod to Covid vaccine for emergency use
AstraZeneca Pharma India Q3 results: Net profit declines 21% to Rs 21 cr
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
AnnouncementsCompliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
AnnouncementsDec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | |
---|---|---|---|---|---|
Total Income | 203.18 | 214.19 | 196.23 | 198.28 | 227.32 |
Total Income Growth (%) | -5.14 | 9.15 | -1.04 | -12.78 | 7.41 |
Total Expenses | 174.62 | 178.34 | 169.57 | 184.66 | 191.87 |
Total Expenses Growth (%) | -2.09 | 5.18 | -8.17 | -3.76 | 6.85 |
EBIT | 28.56 | 35.85 | 26.66 | 13.62 | 35.45 |
EBIT Growth (%) | -20.32 | 34.47 | 95.74 | -61.59 | 10.52 |
Profit after Tax (PAT) | 21.05 | 26.34 | 18.63 | 9.58 | 26.70 |
PAT Growth (%) | -20.07 | 41.34 | 94.55 | -64.13 | 85.23 |
EBIT Margin (%) | 14.06 | 16.74 | 13.59 | 6.87 | 15.60 |
Net Profit Margin (%) | 10.36 | 12.30 | 9.50 | 4.83 | 11.75 |
Basic EPS (₹) | 8.42 | 10.54 | 7.45 | 3.83 | 10.68 |
All figures in Rs Cr, unless mentioned otherwise
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 26.05% towards employee cost in the year ending Mar 31, 2020. (Source: Standalone Financials)Quarterly Revenue Growth Comparison
Company reported income decline on both quarterly & yearly basis. Total income for Dec 31, 2020 quarter was Rs 203.18 cr which is a decrease of -5.14% QoQ and -10.62% YoY. (Source: Standalone Financials)Annual | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
---|---|---|---|---|---|
Total Assets | 706.36 | 561.80 | 460.54 | 415.49 | 405.72 |
Total Assets Growth (%) | 25.73 | 21.99 | 10.84 | 2.41 | -1.43 |
Total Liabilities | 341.92 | 261.00 | 213.61 | 192.62 | 249.71 |
Total Liabilities Growth (%) | 31.00 | 22.19 | 10.90 | -22.86 | -4.27 |
Total Equity | 364.44 | 300.80 | 246.93 | 222.87 | 156.01 |
Total Equity Growth (%) | 21.16 | 21.82 | 10.80 | 42.86 | 3.48 |
Current Ratio (x) | 1.66 | 1.56 | 1.55 | 1.32 | 1.08 |
Total Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Contingent Liabilities | 69.19 | 32.57 | 11.85 | 17.25 | 42.75 |
All figures in Rs Cr, unless mentioned otherwise
Contingent Liabilities Coverage
Company has sufficient cash reserves to pay off its contingent liabilities. (Source: Standalone Financials)Zero Debt Burden
Company has no debt since last 5 years. (Source: Standalone Financials)Annual | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
---|---|---|---|---|---|
Net Cash flow from Operating Activities | 87.42 | 54.98 | 8.79 | 38.10 | 56.99 |
Net Cash used in Investing Activities | -170.80 | 4.28 | -9.36 | 0.25 | -3.61 |
Net Cash flow from Financing Activities | -6.36 | - | 0.00 | 0.00 | -0.51 |
Net Cash Flow | -89.74 | 59.26 | -0.57 | 38.35 | 52.87 |
Closing Cash & Cash Equivalent | 83.50 | 173.24 | 113.98 | 114.55 | 76.20 |
Closing Cash & Cash Equivalent Growth (%) | -51.80 | 51.99 | -0.50 | 50.33 | 226.59 |
Total Debt/ CFO (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
All figures in Rs Cr, unless mentioned otherwise
Annual | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
---|---|---|---|---|---|
Return on Equity (%) | 19.81 | 18.10 | 10.49 | 8.99 | 3.37 |
Return on Capital Employed (%) | 30.36 | 23.99 | 17.27 | 15.76 | 3.66 |
Return on Assets (%) | 10.22 | 9.69 | 5.62 | 4.82 | 1.29 |
Interest Coverage Ratio (x) | 100.97 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover Ratio (x) | 117.76 | 129.63 | 123.98 | 130.85 | 138.94 |
Price to Earnings (x) | 83.33 | 92.59 | 90.09 | 117.65 | 555.56 |
Price to Book (x) | 16.41 | 16.61 | 9.38 | 10.55 | 18.53 |
EV/EBITDA (x) | 42.83 | 55.06 | 37.42 | 43.56 | 121.38 |
EBITDA Margin (%) | 16.07 | 12.02 | 10.25 | 9.44 | 4.11 |
Building-up Cash Reserves
Company has consistently increased ROE in last 5 years with majority of profits being added to its reserves last year. (Source: Standalone Financials)Found Financials useful?
Stochastic Crossover
Bullish signal on weekly chart
Appeared on: 5 Mar 2021
Region: Oversold (Below 20)
Average price gain of 11.82% within 7 weeks of Bullish signal in last 10 years
5 Day EMA Crossover
Bearish signal on daily chart
Appeared on: 5 Mar 2021
5D EMA: 3477.10
Average price decline of -2.64% within 7 days of Bearish signal in last 5 years
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
R1 | 3478.73 | Pivot 3454.87 | S1 | 3414.73 |
R2 | 3518.87 | S2 | 3390.87 | |
R3 | 3582.87 | S3 | 3326.87 |
5 Days | 14 Days | 28 Days |
86.93 | 115.51 | 127.60 |
Found Technicals useful?
Choose from Peers
Choose from Stocks
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of 249.42% as compared to Nifty Midcap 100 which gave a return of 27.48%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 249.42% return as compared to Nifty Pharma which gave investors 42.0% return over 3 year time period. (as of last trading session)MF Ownership as on 31 January 2021
72.51
Amount Invested (in Cr.)
0.68%
% of AUM
0.00
% Change (MoM basis)
11.20
Amount Invested (in Cr.)
0.97%
% of AUM
0.00
% Change (MoM basis)
1.81
Amount Invested (in Cr.)
0.44%
% of AUM
0.00
% Change (MoM basis)
Board Meeting
Quarterly Results
Oct 23, 2020
Interim Dividend
100%
Aug 10, 2020
Board Meeting
Quarterly Results & Interim Dividend
Aug 04, 2020
Announced on | Meeting on |
Oct 23, 2020 | Nov 05, 2020 |
Quarterly Results | |
Aug 04, 2020 | Aug 10, 2020 |
Quarterly Results & Interim Dividend | |
May 12, 2020 | May 18, 2020 |
Audited Results | |
Jan 21, 2020 | Feb 03, 2020 |
Quarterly Results | |
Oct 24, 2019 | Nov 11, 2019 |
Quarterly Results |
Announced on | Ex-Date | Dividend% |
Aug 10, 2020 | Aug 20, 2020 | 100% |
Aug 07, 2019 | Aug 20, 2019 | 50% |
May 12, 2012 | Jul 09, 2012 | 175% |
May 13, 2011 | Jul 07, 2011 | 500% |
Aug 07, 2019 | - | 50% |
Announced on | Ex-Date |
Oct 04, 1995 | Nov 13, 1995 |
Bonus Ratio: 1 share(s) for every 1 shares held |
Announced on | Ex-Date |
May 09, 2006 | Jun 15, 2006 |
Split: Old FV10.0| New FV:2.0 |
No Data Available
Announced on | Meeting on |
Jul 17, 2020 | Aug 10, 2020 |
- | |
May 27, 2020 | Jun 29, 2020 |
- | |
Jul 11, 2019 | Aug 07, 2019 |
- | |
Aug 14, 2018 | Sep 10, 2018 |
Book closure from Sep 3, 2018 to Sep 10, 2018 | |
Aug 09, 2017 | Sep 13, 2017 |
Book closure from Sep 6, 2017 to Sep 13, 2017 |
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 8,596.50 Crore) operating in Pharmaceuticals sector.
AstraZeneca Pharma India Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2020.
For the quarter ended 31-12-2020, the company has reported a Standalone Total Income of Rs 203.18 Crore, down 5.14 % from last quarter Total Income of Rs 214.19 Crore and down 10.62 % from last year same quarter Total Income of Rs 227.32 Crore. Company has reported net profit after tax of Rs 21.05 Crore in latest quarter.
The company’s top management includes Mr.Narayan K Seshadri, Mr.Gagandeep Singh Bedi, Mr.Rajesh Marwaha, Mr.Ankush Nandra, Ms.Weiying Sarah Wang, Ms.Revathy Ashok, Ms.Kimsuka Narsimhan. Company has Price Waterhouse & Co Chartered Accountants LLP as its auditors. As on 31-12-2020, the company has a total of 2.50 Crore shares outstanding.
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 8,596.50 Crore) operating in Pharmaceuticals sector. Show More
Industry
Key Indices Listed On
Nifty 500, S&P BSE 500, Nifty Alpha 50, S&P BSE 250 LargeMidCap Index (INR), S&P BSE SmallCap
Address
Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,Bengaluru, Karnataka - 560045
Ankush Nandra
Non Executive DirectorGagandeep Singh Bedi
Managing DirectorKimsuka Narsimhan
Independent DirectorNarayan K Seshadri
ChairmanAstraZeneca Pharma India Ltd. share price moved down by -0.55% from its previous close of Rs 3,457.60. AstraZeneca Pharma India Ltd. stock last traded price is 3,438.60
Share Price | Value |
---|---|
Today/Current/Last | 3,438.60 |
Previous Day | 3,457.60 |
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.
This is a ratio arrived at by dividing the current market price of a stock by its latest (annual or annualized) earnings per share. Here we have taken the TTM (trailing twelve months) adjusted earnings per share.
Earnings per share (TTM) tells the profit after tax earned on a per share basis by a stock over the last twelve months or four quarters.
MCap or Market capitalization of a stock is calculated by multiplying the total number of shares outstanding of that particular stock with its current market price.
This is the ranking of a company within its sector based on MCap or Market capitalization. Higher the market capitalization of a company, higher the rank it is assigned.
Price to Book represents the ratio of current market price of a stock to its book value per share. The book value itself is arrived at by dividing the net worth of a company by the total number of shares outstanding of the company at that time.
Dividend Yield calculates the amount of full year dividend declared by a company as a percentage of the current market price of a stock. All other things being equal, higher the dividend yield of the stock, the better it is for investors.
Face value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value.
Beta (β) is a measure of systematic risk. It describes the responsiveness of a stock to fluctuations in the market. Beta coefficient of more than 1 denotes that a security is more volatile than its benchmark and less than 0 signifies that security return is not correlated to market movement.
Volume Weighted Average Price represents the average price of a security over a particular time period (example one trading day) weighted by the volume traded at each price point.
This represents the 52 week high and low price of the security. It is also the 1 year high and low of the security. This represents the highest and lowest price touched by the security during the past 52 weeks or 1 year including today.
Book value represents the value arrived at by subtracting the total liabilities from the total assets of the company. On dividing this value with the total number of shares outstanding for the company, we can arrive at book value per share. Book value is also known as Net Asset Value of a company.
This is a ratio of market capitalisation of a company’s stock to its annual sales. The market capitalization here is taken for the fully paid-up equity share of the company.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Pivot points are indicative support and resistance levels which are calculated on basis of previous day’s high, low and closing prices. Pivot level for Monday’s trade would be based on Friday’s prices and Monday’s, high, low and close price would go into calculation of pivot levels for Tuesday’s trading session.
There are two underlying assumptions in pivot points. First, the specific price level indicated by R1, R2 and R3 may act as a barrier or resistance in an uptrend. So, if a stock moves up above these pivots levels, the uptrend gets confirmed. Second these specific price levels may see an increased activity, hence may be used as levels to book profit by traders with a long positions. For traders with short position, these points are often helpful in determining what should be the stop loss for a trade.
Similarly, in case of support levels as indicated by S1, S2 and S3, they may act as price level where a stock might get a breather when it is slipping southward. In case these supports levels are broken it is a confirmation of a down trend. The stock may also see increased activity close to pivot levels. They may be used by trader may use them to put stop loss for a long trade. If a trader has short position, the pivot level may help in determine a level, where profit may be booked.
Like any other technical indicator, pivots levels cannot and should not be used as single factor while taking a trading decision. They should be combined with other technical indicators. It could be short term moving averages, stochastic, moving average convergence divergence (MACD) or overbought level as indicated by relative strength index (RSI). For example, if a breakdown of support level (S1, S2 or S3) is accompanied with stock price also moving below its short term moving average or stochastic on daily charts giving a sell signal, it would add to weightage to the decision of taking a short trade.